I've noticed that most of the combo trials being done are collaborations like ours today in which there is no monetary deal and the costs are split then the subsequent trial results that come will determine any future monetary deal. ADRO just entered a similar deal with Merck and ADRO already has a similiar deal with Bristol. The +$1 billion monetary deals ADRO struck were for monotherapy develpment of lung and prostate with J&J. We need a big monetary deal on our AXAL cervical cancer monotherapy construct that is late stage and could see Europe approval in the next 12 months. These combo deals like we saw today are positive, but frankly they are becoming a dime a dozen and the BPs with PD1 are collaborating left and right on combo deals, but they are not paying anything at this point, just waiting to see. The combo space has become that much more competitive, as evidenced today with ADXS making their LLM for HPV apparently better. The unfortunate part is that while we have these positive developments and improvements, the costs and time decay of them to date has over-ridden any value shareholders see as evidenced by the stock being down 30% from the average cost of all the offerings under DO. Hopefully, we will get a material monetary deal on AXAL Europe in which a BP puts real money on the line, which is the confidence we needs to bolster our valuation, instead of more new combo trials which will cost a lot to ADXS shareholders with BP showing no monetary committment or skin in the game.
News 
Market Data 
Discover 
